PT - JOURNAL ARTICLE AU - Surabhi Madan AU - Amit Patel AU - Kartikae Sharan AU - Shayon Ghosh AU - Vishnu Venugopal AU - Nitesh Shah AU - Bhagyesh Shah AU - Vipul Thakkar AU - Rashmi Chovatiya AU - Hardik Shah AU - Pradip Dabhi AU - Minesh Patel AU - Bhowmik Meghnathi AU - Vineet Sankhla AU - Vipul Kapoor AU - Tejas Patel AU - Maulik Soni AU - Nirav Bapat AU - Kaivan Shah AU - Ritanshu Chandarana AU - Parloop Bhatt AU - Manish Rana TI - Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir AID - 10.1101/2021.07.15.21260600 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.15.21260600 4099 - http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260600.short 4100 - http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260600.full AB - Background Remdesivir (RDV) in coronavirus disease 2019 (COVID-19) has been found to be beneficial in patients with severe disease; however, its role in mild-moderate disease and its optimal timing need to be identified.Objective To assess the course of illness and final outcome in patients who received RDV at various stages of illness, and compare it to the non-RDV group.Methods This is a retrospective data analysis of 1262 COVID-19 patients hospitalized from May5, 2020 to August 31, 2020. The primary outcomes were progression to mechanical ventilation (MV) or death. Kaplan Meier survival analysis and log rank test were used for evaluating primary outcomes.Results 398 patients comprised the RDV group and 260 patients comprised the non-RDV group. 2/3rd of patients were above 50 years of age in both the groups and 3/4th patients were male. Mortality rate was 5.8% in RDV group (10.4% in non-RDV group). Mortality rate was 3.6%, 4% and 16.7% when RDV was started within 5 days, 5 to 10 days and after 10 days of symptom onset respectively. Fewer patients in RDV group progressed to MV (4.0% v/s 8.2%). Earlier discharge occurred in RDV group. Use of supplemental oxygen was observed in 44.7% patients in RDV group (54.2% in non-RDV group). No significant adverse events were observed with RDV. Survival analysis showed that probability of event (death) was significant for patients with hypertension (HT) and/or diabetes mellitus (DM) in RDV group.Conclusion Early initiation of RDV is associated with shorter hospital stay, lower mortality as well as reduced need for supplemental oxygen and mechanical ventilation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo internal or external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CIMS (Care Institute of Medical Sciences) hospital ethics committee (CTRI/2020/05/025247).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available in digital form and will be provided if required